Clindamycin and Tovorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 1, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Clindamycin
Tovorafenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Tovorafenib (Ojemda) can speed up a liver enzyme called CYP3A that your body uses to process many other medicines. Clindamycin is broken down by that same enzyme. So when the two are taken together, your body may clear clindamycin faster, which could leave less of it in your system to fight your infection.
This is based on theory and modeling, not lots of real-world cases, so please don't panic. The main worry is that clindamycin might not work as well. Your care team can manage this by watching to make sure your infection is improving, and if needed, adjusting your treatment. Talk with your pharmacist or doctor before changing anything.
Mechanism: Tovorafenib is a CYP3A inducer; clindamycin is partly a CYP3A4 substrate. Induction may increase clindamycin clearance, lowering its exposure (AUC/Cmax) and potentially reducing antibacterial efficacy.
- Direction: Reduced clindamycin effect (possible therapeutic failure).
- Magnitude: Not directly established; modeling with midazolam predicted at least a 20% decrease in Cmax/AUC.
- Onset: Unspecified.
- Evidence: Theoretical / model-informed.
Management: Avoid coadministration where minimal concentration changes could cause serious failure. If unavoidable, monitor for loss of antibacterial efficacy and consider an alternative anti-infective or individualized therapy per the care team.
What happens
Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI
Interaction Deep Dive
Do not give tovorafenib (a CYP3A inducer) together with certain CYP3A substrates in situations where even small changes in concentration could result in serious therapeutic failure. When tovorafenib is used alongside CYP3A substrates that have a narrow therapeutic index (NTI), exposure to the NTI CYP3A substrate may fall, potentially diminishing the efficacy of that CYP3A4 substrate with NTI. Should coadministration be necessary, watch patients for any loss of efficacy. A model informed drug interaction study predicts that the steady-state Cmax and AUC of midazolam (a CYP3A4 substrate) will drop by at least 20% when it is coadministered with tovorafenib1.
Why it happens (mechanism)
Induction of CYP3A-mediated metabolism by tovorafenib
How to manage this interaction
The practical picture: Because tovorafenib can lower clindamycin levels, the main goal is making sure your infection is still being treated effectively.
- Keep taking both medicines exactly as prescribed unless your care team tells you otherwise.
- Your team may watch more closely for signs the infection isn't improving (fever, worsening redness, pain, or drainage).
- They may choose a different antibiotic, or tailor and adjust your treatment to your situation.
What to do: Let your pharmacist or prescriber know you take both, and report any signs your infection is not getting better.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Using a model informed approach in a drug interaction study, it is predicted that the steady-state Cmax and AUC of midazolam (a CYP3A4 substrate) will decrease by at least 20% when it is coadministered with tovorafenib 1.
Common questions
Can I take Clindamycin and Tovorafenib together?
Tovorafenib may lower clindamycin levels and make it less effective, so your care team may monitor your infection closely or pick an alternative. Keep taking both as prescribed and report any lack of improvement. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Clindamycin and Tovorafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Clindamycin and Tovorafenib interaction managed?
The practical picture: Because tovorafenib can lower clindamycin levels, the main goal is making sure your infection is still being treated effectively. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Your team may watch more closely for signs the infection isn't improving (fever, worsening redness, pain, or drainage). They may choose a different antibio… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Clindamycin or Tovorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: OJEMDA oral tablets, oral suspension, tovorafenib oral tablets, oral suspension. Day One Biopharmaceuticals, Inc.(Per FDA), Brisbane, CA, 2024. DailyMed
Keep reading about Clindamycin
Keep reading about Tovorafenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist